Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, And Segment Forecasts, 2023

The global sarcoma drugs market size is expected to be valued at USD 2534.5 million by 2030, as per a new report by Grand View Research, Inc.., progressing at a CAGR of 8.9% from 2023 to 2030. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.

Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year.

For over 40 years, the mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. The introduction of targeted therapy has revolutionized the treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period.

Sarcoma Drugs Market Report Highlights:

EU5 will remain the second largest market with more than 20% share by 2022. The growth of the segment can be attributed to the rising incidence of STS, uptake of targeted therapies, and increasing R&D activities
Eli Lilly's Lartuvo has displaced standard doxorubicin therapy as front-line STS treatment and is anticipated to maintain its prominence in the market over the forecast period
Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the remaining in Phase I and Pre-clinical trials
The potential role for use of immuno-oncology agents in sarcomas is currently under evaluation in Phase I/II clinical trials
Drugs with novel targets in early-phase development include Novartis's Afinitor (mTOR inhibitor), Tesaro's Zejula (PARP inhibitor), Amgen's Imlygic (gene therapy), and Pfizer's Crizotinib (ALK and MET tyrosine kinases inhibitor)

Product Code: GVR-2-68038-528-1

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
- 1.1.1. Treatment type
- 1.1.2. Distribution channel
- 1.1.3. Regional scope
- 1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Treatment type outlook
- 2.2.2. Distribution channel outlook
- 2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Sarcoma Drugs Market: Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
- 3.3.1. Reimbursement framework
3.4. Market Dynamics
3.5. Sarcoma Drugs Market Analysis Tools
- 3.5.1. Industry Analysis - Porter's
  - 3.5.1.1. Supplier power
  - 3.5.1.2. Buyer power
  - 3.5.1.3. Substitution threat
  - 3.5.1.4. Threat of new entrant
  - 3.5.1.5. Competitive rivalry
- 3.5.2. PESTEL Analysis
  - 3.5.2.1. Political landscape
  - 3.5.2.2. Technological landscape
  - 3.5.2.3. Economic Landscape

Chapter 4. Sarcoma Drugs Market: Treatment Type Estimates & Trend Analysis

4.1. Sarcoma Drugs Market: Key Takeaways
4.2. Sarcoma Drugs Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Chemotherapy
- 4.3.1. Chemotherapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Targeted therapy
- 4.4.1. Targeted therapy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Sarcoma Drugs Market: Distribution Channel Estimates & Trend Analysis

5.1. Sarcoma Drugs Market: Key Takeaways
5.2. Sarcoma Drugs Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Hospital pharmacy
- 5.3.1. Hospital pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Retail pharmacy
- 5.4.1. Retail pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Online pharmacy
- 5.5.1. Online pharmacy market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Sarcoma Drugs Market: Regional Estimates & Trend Analysis

6.1. Regional Outlook
6.2. Sarcoma Drugs Market: by Region: Key Marketplace Takeaway
6.3. North America
- 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.2. U.S.
  - 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.3.3. Canada
  - 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
- 6.4.1. UK
  - 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.2. Germany
  - 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.3. France
  - 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.4. Italy
  - 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.5. Spain
  - 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.6. Sweden
  - 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.7. Norway
  - 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.4.8. Denmark
  - 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
- 6.5.1. Japan
  - 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.2. China
  - 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.3. India
  - 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.4. Australia
  - 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.5. Thailand
  - 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.5.6. South Korea
  - 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
- 6.6.1. Brazil
  - 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.2. Mexico
  - 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.6.3. Argentina
  - 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
- 6.7.1. Saudi Arabia
  - 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.2. South Africa
  - 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.3. UAE
  - 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 6.7.4. Kuwait
  - 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
- 7.2.1. Pfizer Inc.
  - 7.2.1.1. Company overview
  - 7.2.1.2. Financial performance
  - 7.2.1.3. Product benchmarking
  - 7.2.1.4. Strategic initiatives
- 7.2.2. Novartis International AG
  - 7.2.2.1. Company overview
  - 7.2.2.2. Financial performance
  - 7.2.2.3. Product benchmarking
  - 7.2.2.4. Strategic initiatives
- 7.2.3. Eli Lilly and Company
  - 7.2.3.1. Company overview
  - 7.2.3.2. Financial performance
  - 7.2.3.3. Product benchmarking
  - 7.2.3.4. Strategic initiatives
- 7.2.4. Bayer AG
  - 7.2.4.1. Company overview
  - 7.2.4.2. Financial performance
  - 7.2.4.3. Product benchmarking
  - 7.2.4.4. Strategic initiatives
- 7.2.5. Eisai Co.
  - 7.2.5.1. Company overview
  - 7.2.5.2. Financial performance
  - 7.2.5.3. Product benchmarking
  - 7.2.5.4. Strategic initiatives
- 7.2.6. Johnson & Johnson
  - 7.2.6.1. Company overview
  - 7.2.6.2. Financial performance
  - 7.2.6.3. Product benchmarking
  - 7.2.6.4. Strategic initiatives
- 7.2.7. Merck & Co. Inc
  - 7.2.7.1. Company overview
  - 7.2.7.2. Financial performance
  - 7.2.7.3. Product benchmarking
  - 7.2.7.4. Strategic initiatives
- 7.2.8. Daiichi Sankyo Company, Limited
  - 7.2.8.1. Company overview
  - 7.2.8.2. Financial performance
  - 7.2.8.3. Product benchmarking
  - 7.2.8.4. Strategic initiatives

Product Code: GVR-2-68038-528-1

List of Tables

Table 1 List of Abbreviations
Table 2 North America sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 3 North America sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 4 North America sarcoma drugs market: by region, 2018 - 2030 (USD Million)
Table 5 U.S. sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 6 U.S. sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 7 Canada sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 8 Canada sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 9 Europe sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 10 Europe sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 11 Europe sarcoma drugs market: by region, 2018 - 2030 (USD Million)
Table 12 Germany sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 13 Germany sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 14 UK sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 15 UK sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 16 France sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 17 France sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 18 Italy sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 19 Italy sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 20 Spain sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 21 Spain sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 22 Sweden sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 23 Sweden sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 24 Norway sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 25 Norway sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 26 Denmark sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 27 Denmark sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 28 Asia Pacific sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 29 Asia Pacific sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 30 Asia Pacific sarcoma drugs market: by region, 2018 - 2030 (USD Million)
Table 31 China sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 32 China sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 33 China sarcoma drugs market: by application, 2018 - 2030 (USD Million)
Table 34 Japan sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 35 Japan sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 36 Japan sarcoma drugs market: by application, 2018 - 2030 (USD Million)
Table 37 India sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 38 India sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 39 Australia sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 40 Australia sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 41 Thailand sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 42 Thailand sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 43 South Korea sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 44 South Korea sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 45 Latin America sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 46 Latin America sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 47 Latin America sarcoma drugs market: by region, 2018 - 2030 (USD Million)
Table 48 Brazil sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 49 Brazil sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 50 Mexico sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 51 Mexico sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 52 Argentina sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 53 Argentina sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 55 Middle East and Africa sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 56 Middle East and Africa sarcoma drugs market: by region, 2018 - 2030 (USD Million)
Table 57 South Africa sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 58 South Africa sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 59 Saudi Arabia sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 60 Saudi Arabia sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 61 UAE sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 62 UAE sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)
Table 63 Kuwait sarcoma drugs market: by treatment type, 2018 - 2030 (USD Million)
Table 64 Kuwait sarcoma drugs market: by distribution channel, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Sarcoma drugs market: Market outlook
Fig. 9 Sarcoma drugs market: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Sarcoma drugs market: driver impact
Fig. 15 Sarcoma drugs market: restraint impact
Fig. 16 Sarcoma drugs market: Strategic Initiatives analysis
Fig. 17 Sarcoma drugs market: Treatment type movement analysis
Fig. 18 Sarcoma drugs market: Treatment type outlook and key takeaways
Fig. 19 Chemotherapy market estimates and forecasts, 2018 - 2030
Fig. 20 Targeted therapy & others market estimates and forecasts, 2018 - 2030
Fig. 21 Sarcoma drugs market: Distribution channel movement analysis
Fig. 22 Sarcoma drugs market: Distribution channel outlook and key takeaways
Fig. 23 Hospital pharmacy market estimates and forecasts, 2018 - 2030
Fig. 24 Retail pharmacy market estimates and forecasts, 2018 - 2030
Fig. 25 Online pharmacy market estimates and forecasts, 2018 - 2030
Fig. 26 Global Sarcoma drugs market: Regional movement analysis
Fig. 27 Global Sarcoma drugs market: Regional outlook and key takeaways
Fig. 28 North America market estimates and forecasts, 2018 - 2030
Fig. 29 U.S. market estimates and forecasts, 2018 - 2030
Fig. 30 Canada market estimates and forecasts, 2018 - 2030
Fig. 31 Europe market estimates and forecasts, 2018 - 2030
Fig. 32 UK market estimates and forecasts, 2018 - 2030
Fig. 33 Germany market estimates and forecasts, 2018 - 2030
Fig. 34 France market estimates and forecasts, 2018 - 2030
Fig. 35 Italy market estimates and forecasts, 2018 - 2030
Fig. 36 Spain market estimates and forecasts, 2018 - 2030
Fig. 37 Sweden market estimates and forecasts, 2018 - 2030
Fig. 38 Norway market estimates and forecasts, 2018 - 2030
Fig. 39 Denmark market estimates and forecasts, 2018 - 2030
Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030
Fig. 41 Japan market estimates and forecasts, 2018 - 2030
Fig. 42 China market estimates and forecasts, 2018 - 2030
Fig. 43 India market estimates and forecasts, 2018 - 2030
Fig. 44 Australia market estimates and forecasts, 2018 - 2030
Fig. 45 Thailand market estimates and forecasts, 2018 - 2030
Fig. 46 South Korea market estimates and forecasts, 2018 - 2030
Fig. 47 Latin America market estimates and forecasts, 2018 - 2030
Fig. 48 Brazil market estimates and forecasts, 2018 - 2030
Fig. 49 Mexico market estimates and forecasts, 2018 - 2030
Fig. 50 Argentina market estimates and forecasts, 2018 - 2030
Fig. 51 Middle East and Africa. market estimates and forecasts, 2018 - 2030
Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030
Fig. 53 South Africa market estimates and forecasts, 2018 - 2030
Fig. 54 UAE market estimates and forecasts, 2018 - 2030
Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030

Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, And Segment Forecasts, 2023 - 2030

Description

Table of Contents

List of Tables

Sarcoma Drugs Market Growth & Trends:

Sarcoma Drugs Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Sarcoma Drugs Market: Variables, Trends & Scope

Chapter 4. Sarcoma Drugs Market: Treatment Type Estimates & Trend Analysis

Chapter 5. Sarcoma Drugs Market: Distribution Channel Estimates & Trend Analysis

Chapter 6. Sarcoma Drugs Market: Regional Estimates & Trend Analysis

Chapter 7. Competitive Landscape

List of Tables

List of Figures